Kungsbron 1, D5
Stockholm 111 22
Sweden
46 84 11 30 05
https://www.calliditas.se
Settore/i:
Settore:
Impiegati a tempo pieno: 192
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Renee Aguiar-Lucander | Chief Executive Officer | 8,99M | N/D | 1962 |
Mr. Fredrik Johansson | Chief Financial Officer | N/D | N/D | 1977 |
Dr. Johan Haggblad Ph.D. | Chief Scientific Officer | 1,66M | N/D | 1958 |
Mr. Brian Gorman | Group General Counsel | N/D | N/D | 1976 |
Ms. Sandra Frithiof | Head of Human Resources | N/D | N/D | 1975 |
Ms. Ann-Kristin Myde BSc | Head of Clinical Development & VP of Project Management | N/D | N/D | 1955 |
Dr. Krassimir Mitchev | Head of Medical Affairs | N/D | N/D | 1959 |
Dr. Richard S. Philipson M.D. | Chief Medical Officer | N/D | N/D | 1964 |
Ms. Teona Johnson | Head of US Marketing | N/D | N/D | N/D |
Mr. David Ferraro | Head of US Sales | N/D | N/D | N/D |
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
L'ISS Governance QualityScore di Calliditas Therapeutics AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.